News & Updates

Show Multimedia Only

Ozanimod effective as induction, maintenance therapy for ulcerative colitis

18 Oct 2021 by

A once-daily oral formulation of ozanimod, a selective sphingosine-1-phosphate (S1P) receptor modulator, outdid placebo as induction and maintenance therapy for moderate-to-severe* active ulcerative colitis (UC), findings from the phase III True North study have shown.

18 Oct 2021

3-day remdesivir prevents hospitalization, death in COVID-19

18 Oct 2021 by

A 3-day course of remdesivir may help stave off COVID-19–related hospitalization and death, according to results of the phase III PINETREE study.

18 Oct 2021

Drug-delivery device implant works well for neovascular AMD

18 Oct 2021 by

An ocular implant that continuously dispenses an antivascular endothelial growth factor (anti-VEGF) therapy into the vitreous performs well in the management of neovascular age-related macular degeneration, affording disease control and achieving vision and anatomical outcomes similar to that obtained with monthly intravitreal injections, as shown in the phase III ARCHWAY trial.

18 Oct 2021

Warfarin plus aspirin tied to higher bleeding risk than monotherapy in AF patients

18 Oct 2021

The combination of aspirin and warfarin therapy appears to increase the risk of bleeding, with little benefit in reducing stroke or cardiovascular events compared with warfarin alone in patients with atrial fibrillation (AF), reveals a study.

18 Oct 2021

Antiplatelet plus anticoagulant therapy linked to better outcomes in COVID-19

18 Oct 2021

Hospitalized patients with COVID-19 who receive antiplatelet and anticoagulant drugs concurrently may fare better than those given only therapeutic anticoagulation, according to a study.

18 Oct 2021

Tapinarof a new kid on the block for plaque psoriasis

18 Oct 2021 by

Treatment with the nonsteroidal topical cream tapinarof 1% for up to 52 weeks helps control plaque psoriasis in the phase III PSOARING 3 trial.

18 Oct 2021

Acute kidney injury more prevalent among patients on antibiotic combo vs monotherapy

16 Oct 2021

Treatment with the combination of vancomycin and piperacillin/tazobactam (VAN + PTZ) appears to be associated with a greater prevalence of acute kidney injury as compared with VAN or PTZ monotherapy or with the concurrent use of VAN and cefepime or carbapenem, a study reports.

16 Oct 2021

Abrocitinib trumps dupilumab for itch relief in eczema

16 Oct 2021 by

The oral selective JAK*1 inhibitor abrocitinib is superior to dupilumab for relieving itch and achieving skin clearance in people with moderate-to-severe atopic dermatitis (AD), according to results from a head-to-head comparison in the JADE DARE trial presented at EADV 2021.

16 Oct 2021